Published on 21/12/2025
Recent Trends in GCP Inspections in China: Key Findings and Lessons
Introduction
Good Clinical Practice (GCP) inspections play a central role in ensuring the credibility of clinical trial data and the protection of participants. In China, the National Medical Products Administration (NMPA) has expanded its GCP inspection program significantly in recent years, reflecting the country’s growing role in global clinical research. With reforms to align with ICH E6(R2), the NMPA now applies rigorous inspection standards similar to those of the FDA and EMA. These inspections cover investigator sites, contract research organizations (CROs), and sponsors, focusing on data integrity, patient safety, and ethical compliance. This article analyzes recent trends in GCP inspections in China, highlighting common findings, regulatory expectations, and best practices for inspection readiness.
Background and Regulatory Framework
Evolution of GCP Oversight
Historically, GCP inspections in China were limited in scope and frequency. With the rise of multinational clinical trials, the NMPA expanded its GCP inspection program, introducing risk-based approaches and strengthening inspector training. The 2019 Drug Administration Law formalized inspection authority and penalties for non-compliance.
NMPA’s Inspection Priorities
The NMPA focuses on critical areas such as informed consent, source data verification, adverse event reporting, and trial master file
Case Example: Oncology Trial Inspection
In a 2021 oncology trial, NMPA inspectors found incomplete adverse event documentation and inadequate monitoring reports. The sponsor was required to implement corrective and preventive actions (CAPA) and retrain site staff, underscoring the importance of QA frameworks.
Core Clinical Trial Insights
Common Findings in NMPA Inspections
Recent inspections have highlighted recurring issues:
✔️ Incomplete or missing informed consent forms
✔️ Discrepancies between source data and case report forms
✔️ Inadequate adverse event documentation
✔️ Poorly maintained TMFs and missing essential documents
✔️ Limited QA oversight and monitoring gaps
✔️ Insufficient training records for investigators and CRCs
These findings mirror inspection results from FDA and EMA, indicating global convergence in GCP enforcement.
Inspection of Investigator Sites
Investigator sites, especially Tier-2 hospitals, often face challenges in maintaining complete documentation and training compliance. Inspectors emphasize adherence to SOPs, accurate recordkeeping, and ethical committee approvals. Tier-1 hospitals generally demonstrate stronger compliance due to more established QA structures.
CRO and Sponsor Oversight
The NMPA increasingly inspects CROs and sponsors, assessing monitoring reports, data management practices, and pharmacovigilance systems. Sponsors are held accountable for ensuring CRO compliance, reflecting ICH E6(R2)’s emphasis on oversight responsibilities.
Data Integrity as a Central Theme
Data integrity remains a top inspection priority. Findings often involve inadequate audit trails, missing source documents, and poor documentation of protocol deviations. The NMPA requires validated electronic systems and emphasizes traceability of all data entries.
Ethics Committees Under Scrutiny
Inspections now include reviews of ethics committee operations, training records, and SOPs. Committees with inconsistent review standards or incomplete meeting documentation are flagged for corrective action, reinforcing their critical role in protecting patient rights.
Best Practices & Preventive Measures
Sponsors should:
✔️ Conduct mock inspections and internal audits
✔️ Ensure complete and accurate TMF documentation
✔️ Maintain validated electronic systems with audit trails
✔️ Provide regular GCP training for investigators and CRCs
✔️ Strengthen CRO oversight through QA audits
✔️ Prepare inspection readiness plans at both sponsor and site levels
Proactive measures reduce inspection risks and build credibility with regulators.
Scientific & Regulatory Evidence
China’s GCP inspection system is aligned with ICH E6(R2), WHO GCP, and global regulatory frameworks. Comparative evidence from FDA and EMA inspections shows convergence in findings, particularly in informed consent, data integrity, and pharmacovigilance. The 2019 Drug Administration Law provides NMPA with enhanced enforcement authority, strengthening compliance expectations.
Special Considerations
Rare disease and pediatric trials require special attention in inspections due to vulnerable populations and complex consent processes. Decentralized trial models, increasingly used in China, face inspection challenges related to data localization and electronic consent validation.
When Sponsors Should Seek Regulatory Advice
Sponsors should seek regulatory advice from the NMPA during trial planning and before initiating multicenter studies. Consultations clarify expectations for TMF management, CRO oversight, and data localization compliance. Early engagement minimizes inspection risks.
Case Studies
Case Study 1: CRO Inspection in a Cardiovascular Trial
A CRO managing a cardiovascular trial was inspected by the NMPA in 2022. Inspectors identified missing monitoring reports and inadequate SAE follow-up. The sponsor implemented CAPAs, including new SOPs and enhanced CRO oversight, ensuring compliance in subsequent audits.
Case Study 2: Site Inspection in a Rare Disease Trial
A rare disease trial site was flagged for incomplete consent documentation and poor source data management. With targeted training and sponsor-led audits, the site improved compliance, and data from the trial were accepted in multinational submissions.
FAQs
1. What are the main findings in NMPA GCP inspections?
Common findings include missing informed consent, poor TMF documentation, data integrity issues, inadequate SAE reporting, and insufficient staff training.
2. How does the NMPA conduct inspections?
The NMPA uses risk-based inspections, including unannounced visits, focusing on high-risk trials such as oncology and rare diseases.
3. Are CROs inspected in China?
Yes, CROs are increasingly inspected to ensure compliance with monitoring, data management, and pharmacovigilance responsibilities.
4. What role do ethics committees play in inspections?
Ethics committees are inspected for SOPs, meeting documentation, and consistency in protocol review, reflecting their role in patient protection.
5. How can sponsors prepare for NMPA inspections?
By conducting mock audits, verifying TMF completeness, maintaining validated systems, and ensuring CRO and site training compliance.
6. How do China’s inspections compare internationally?
Findings in China align with FDA and EMA trends, particularly around informed consent, data integrity, and pharmacovigilance, reflecting global harmonization.
Conclusion & Call-to-Action
NMPA GCP inspections have become more rigorous, transparent, and globally harmonized, shaping the conduct of clinical trials in China. Sponsors must prioritize inspection readiness, robust QA frameworks, and CRO oversight to ensure compliance. Organizations planning trials in China should integrate inspection preparedness into development strategies, safeguarding both regulatory approval and patient trust.